CMEZone.comRebalancing Risk–Benefit With Buprenorphine: An Atypical Opioid Analgesic

1.0 AMA PRA Category 1 Credit™
1.0 ACPE contact hour (0.1 CEU)

Release Date: May 1, 2022
Expiration Date: May 1, 2023

Learning Objectives
After completing this activity, participants should be better able to:

• Describe the pharmacologic and safety differences between conventional and atypical opioids.
• Recognize appropriate patients who might benefit from buprenorphine as a first-line opioid analgesic.
• Understand how to transition opioid therapy from full µ-opioid analgesics to buprenorphine when appropriate.